Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clofazimine

FDA-approved product (capsule, oral), marketed as Lamprene.

Registered studies
50+
Lab records
5
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clofazimine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Leprosy

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Drugs for treatment of lepra
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04BA01; FDA class Antimycobacterial

Repurposing investigation

Clofazimine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis78.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 5 of 5 lab records
Open Clofazimine in ChEMBL Registered studies below
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clofazimine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

    NCT07228702 · start 2026-01-11

    Registered record
    Registry ID
    NCT07228702
    Conditions
    Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    Interventions
    Mycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B); Linezolid (LZD); Sulfamethoxazole/Trimethoprim; Imipenem + Cilastatin; Ceftaroline fosamil; Omadacycline Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Enrolling by invitation
    Start
    2026-01-11
    Completion
    2027-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    InterventionMycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B) +5 more
    PhasePhase 1
    Registry statusEnrolling by invitation

  • 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

    NCT07198685 · start 2025-09-30

    Registered record
    Registry ID
    NCT07198685
    Conditions
    Treat to Target; Treatment Duration
    Interventions
    bedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2028-09-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreat to Target; Treatment Duration
    Interventionbedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin +2 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

    NCT07170800 · start 2025-09-19

    Registered record
    Registry ID
    NCT07170800
    Conditions
    Tuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    Interventions
    JDB0131 100mg; JDB0131 200mg; Delamanid (D)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-19
    Completion
    2026-09-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    InterventionJDB0131 100mg; JDB0131 200mg; Delamanid (D)
    PhasePhase 2
    Registry statusRecruiting

  • A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

    NCT07126639 · start 2025-09-01

    Registered record
    Registry ID
    NCT07126639
    Conditions
    Efficacy and Safety
    Interventions
    bedaquiline; Pretomanid (Pa); linezolid; Moxifloxacin (M); Delamanid (D); Levofloxacin; clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2028-09-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEfficacy and Safety
    Interventionbedaquiline; Pretomanid (Pa); linezolid; Moxifloxacin (M) +3 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

    NCT06819449 · start 2024-12-20

    Registered record
    Registry ID
    NCT06819449
    Conditions
    Leprosy; Mycobacterium Leprae Infection
    Interventions
    Dapsone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-20
    Completion
    2025-12-20
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeprosy; Mycobacterium Leprae Infection
    InterventionDapsone
    PhaseNot applicable
    Registry statusRecruiting

  • Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

    NCT06649721 · start 2024-11-27

    Registered record
    Registry ID
    NCT06649721
    Conditions
    Drug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis
    Interventions
    bedaquiline; delamanid; linezolid; Levofloxacin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-27
    Completion
    2027-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis
    Interventionbedaquiline; delamanid; linezolid; Levofloxacin +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

    NCT06418711 · start 2024-09-11

    Registered record
    Registry ID
    NCT06418711
    Conditions
    MAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculous
    Interventions
    Clofazimine Inhalation Suspension; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2024-09-11
    Completion
    2025-11-10
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculous
    InterventionClofazimine Inhalation Suspension; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

    NCT06081361 · start 2023-12-22

    Registered record
    Registry ID
    NCT06081361
    Conditions
    Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    Interventions
    Bedaquiline; Delamanid; Contezolid; Levofloxacin; Moxifloxacin; Clofazimine; Linezolid; Cycloserine; Prothionamide; Pyrazinamide; Para-Aminosalicylic Acid; Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-12-22
    Completion
    2026-12-31
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    InterventionBedaquiline; Delamanid; Contezolid; Levofloxacin +8 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis

    NCT05556746 · start 2023-11-24

    Registered record
    Registry ID
    NCT05556746
    Conditions
    Tuberculosis, Pulmonary; HIV
    Interventions
    Bedaquiline (BDQ); Clofazimine (CFZ); Pyrazinamide (PZA); Delamanid (DLM); Rifampicin (RIF); Isoniazid (INH); Ethambutol (EMB); Pyrazinamide (PZA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-11-24
    Completion
    2027-01
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; HIV
    InterventionBedaquiline (BDQ); Clofazimine (CFZ); Pyrazinamide (PZA); Delamanid (DLM) +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Linezolid Dosing Strategies in Drug-Resistant TB

    NCT05007821 · start 2022-09-27

    Registered record
    Registry ID
    NCT05007821
    Conditions
    Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
    Interventions
    Linezolid 600 mg; Linezolid 1200 mg (QD); Linezolid 1200 mg (TIW); Bedaquiline 200 mg; Bedaquiline 100 mg; Delamanid 300 mg; Clofazimine 300 mg; Clofazimine 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-09-27
    Completion
    2026-01-13
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
    InterventionLinezolid 600 mg; Linezolid 1200 mg (QD); Linezolid 1200 mg (TIW); Bedaquiline 200 mg +4 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease

    NCT05494957 · start 2022-08-05

    Registered record
    Registry ID
    NCT05494957
    Conditions
    Nontuberculous Mycobacterial Lung Disease
    Interventions
    New regimen(BdqCfzLzd+XY)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-08-05
    Completion
    2025-08-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNontuberculous Mycobacterial Lung Disease
    InterventionNew regimen(BdqCfzLzd+XY)
    PhasePhase 4
    Registry statusUnknown

  • Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)

    NCT05081401 · start 2022-05-23

    Registered record
    Registry ID
    NCT05081401
    Conditions
    Multidrug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis; Pre-XDR-TB
    Interventions
    Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z; A1; A2a; A2b; A2c; A3; A4; A5; B-SOC; B1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-05-23
    Completion
    2027-12-01
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis; Pre-XDR-TB
    InterventionBdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z; A1; A2a; A2b +6 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

    NCT05306223 · start 2022-05-10

    Registered record
    Registry ID
    NCT05306223
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Bedaquiline; Levofloxacin; Linezolid; Cycloserine; Clofazimine; Pyrazinamide; Protionamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-05-10
    Completion
    2025-08-08
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionBedaquiline; Levofloxacin; Linezolid; Cycloserine +3 more
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease

    NCT05294146 · start 2022-02-14

    Registered record
    Registry ID
    NCT05294146
    Conditions
    Nontuberculous Mycobacterial Diseases
    Interventions
    Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-02-14
    Completion
    2023-08-08
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNontuberculous Mycobacterial Diseases
    InterventionClofazimine
    PhasePhase 2
    Registry statusCompleted